Background. Giant cell arteritis (GCA) is a systemic vasculitis of elderly individuals associated with signifi cant morbidity, including blindness, stroke, and myocardial infarction. Previous studies have investigated whether GCA is associated with increased mortality, with confl icting results. The objective of this study is to determine whether GCA, is associated with increased mortality.
G
IANT cell arteritis (GCA) is a systemic vasculitis of elderly individuals associated with signifi cant morbidity. GCA can result in vision loss, peripheral neuropathies, scalp necrosis, altered mental status, congestive heart failure, myocardial infraction, aortitis, aortic aneurysm, and stroke ( 1 -15 ) . Mortality among patients with GCA may be due to cerebral arteritis, coronary arteritis, aortic aneurysm rupture, and thromboembolic events ( 16 -18 ) .
Previous studies have attempted to address whether GCA is associated with increased mortality, with confl icting results ( Table 1 ) . Some studies have concluded that GCA has no effect on mortality ( 8 , 18 -20 , 22 -24 , 27 , 29 , 30 , 32 ) , whereas others suggest that GCA is associated with shortor long-term increases in mortality ( 21 , 25 , 26 , 28 , 31 ) . Many of these studies had limitations such as a small sample size ( 19 , 22 , 25 ) or inclusion of cases with diagnoses not confi rmed by biopsy ( 8 , 19 , 22 , 24 , 26 , 27 , 32 ) .
The purpose of this study was to rigorously evaluate the effect of GCA on mortality by conducting an analysis that included only biopsy-proven cases. Rather than relying on life tables or standardized mortality ratios, we identifi ed 100 controls for each case matched by birth year, gender, and birthplace geography.
Methods
This retrospective cohort study was approved by the University of Utah Institutional Review Board. Our investigation utilized data from the Utah Population Database (UPDB), a unique biomedical and health-related information source which collects all coded medical diagnoses at the University of Utah Health Sciences Center (including inpatients and outpatients), all death certifi cates and the majority of birth certifi cates for the state of Utah ( 33 ) . We searched the UPDB for patients coded for GCA (international classifi cation of diseases [ICD]-9 code 446.5) between 1991 and 2005. In addition, medical records were reviewed for inclusion and exclusion criteria of all potential study subjects initially identifi ed by the UPDB. A subject was included only if his or her chart contained a report of a positive superfi cial temporal artery biopsy. Potential subjects were excluded if they were found to have a negative biopsy, an alternative diagnosis, or insuffi cient clinical data. Collected data also included birth date, diagnosis date, gender, date of death or last follow-up, steroid use, diagnosis of polymyalgia rheumatica (PMR), and ophthalmic fi ndings.
Age-and gender-matched controls for each subject were identifi ed within the UPDB. Controls were also matched to cases by geographic location. Controls were included only if they had a last follow-up date at or beyond the date of disease onset for the case. A random number generator was used to select 100 controls for each case. No control was used for more than one case. Due to the advanced age of one case, the matching birth year had to be expanded by ± 2.5 years to identify 100 controls.
A biostatistician (S.C.A.) analyzed the data using the Kaplan-Meier (product limit) method with a post hoc logrank comparison of the survival of cases and controls. SPSS 15.0 for Windows © (SPSS Inc., Chicago, IL) was used for the analysis. For statistical signifi cance, a was set at 0.05. Five-year survival curves, median survival times, and 95% confi dence intervals were calculated for each group. Survival was measured in days to maximize the sensitivity of the analysis.
Results
Two hundred eighty-eight subjects were initially identifi ed by the UPDB as having an ICD-9 diagnosis of 446.5. After medical record review, GCA diagnosis was confi rmed in 44 subjects. Clinical and demographic data for these 44 cases are summarized in Table 2 . From 236,217 UPDBidentifi ed potential controls, 4,400 were randomly selected.
At the time of this analysis, 21 of the 44 patients were deceased. Analysis of cause of death information revealed that none of the patients had died as a direct result of GCA. Seven patients had died as a result of treatment (gastrointestinal hemorrhage, pneumonia, urinary tract infection, sepsis), eight patients had died as a result of diseases unrelated to GCA or its treatment, and for six patients there were insuffi cient data to make a determination as to the cause of death and its relationship to GCA or its treatment.
The median survival time for the 44 GCA cases was 1,357 days (3.71 years) after diagnosis, compared with 3,044 days (8.34 years) for the controls ( p = .04). The 5-year cumulative survival for the 44 GCA cases was 35%, versus a 5-year survival of 67% for the 4,400 control subjects ( p < .001; Figure 1 ). The cumulative survival in the control group reached 35% at approximately 11.12 years.
Discussion
Our results indicate that a diagnosis of GCA is significantly associated with reduced 5-year survival. The survival rates for cases and controls converge at 11.12 years, suggesting that the adverse affect on survival is present only in the years immediately following diagnosis. At this time survival data beyond this point are limited, making further inferences diffi cult.
When compared with clinical and demographic features described in the literature, the ages of our 44 GCA cases are representative of other study populations with the disease. Although only nine of our 44 patients (20.5%) had a concurrent diagnosis of PMR, many more had symptoms that closely resembled those of PMR. Thus, PMR prevalence in our subjects is consistent with previous reports. The ratio of females to males in our study was 6.3:1, whereas most studies have found this ratio to be closer to 2:1 ( 6 , 12 ). We found that almost 55% of our patients had vision loss, more than other studies have reported, because as ophthalmologists we emphasize vision loss assessment. Another study has reported that GCA patients with vision loss have a reduced survival rate when compared with GCA patients with unchanged vision ( 34 ) . Therefore, patients who present with new visual symptoms should receive especially careful and regular follow-up assessment and care.
Because this study is a retrospective chart review, it lacks uniformity of history taking, chart information, and treatment. An additional limitation is the variability of follow-up time and attrition during the study. Information regarding treatment regimens and duration, as well as presence or absence of standard cardiovascular risk factors, was not consistently available. Nonetheless, this investigation represents a unique approach to the assessment of GCA-associated mortality in that we have compared our GCA cases with controls matched by age, gender, and geography. In order to optimally understand our results in the context of previous studies, it is important to compare the statistical methods previously employed. A number of prior studies relied on life tables, which demographers construct by defi ning an age interval (generally 1 year) and then comparing the number of subjects alive at the beginning of the interval with the number of subjects alive at the interval's end. Age-specifi c mortality rates are calculated if the subjects are divided by age. The 1-year time intervals typically used for life tables have limited sensitivity in an elderly population; for example, the life expectancy of an 80-year-old individual may differ significantly from that of an 80.5-year-old. In addition, the age-specifi c rates in the standard population are based on empirical observations, which will show random fl uctuation ( 35 ) . We have addressed the limitations of using life tables by defi ning a cohort of 100 control subjects for each study subject and then performing a survival analysis of the two groups.
Some previous studies attempted to integrate both early and late effects on longevity, to detect an initial negative effect on survival, or to identify a return to normal age-related mortality rates ( 23 , 24 , 28 , 29 ) . One research team initially observed that patients with GCA had a signifi cantly reduced mortality when compared with the expected mortality rate, but this fi nding was not observed with long-term follow-up ( 24 , 36 ) . We found that the diagnosis of GCA signifi cantly affects the 5-year survival rate; but by 11.12 years the mortality rates of the groups converge, suggesting that the negative impact of GCA on survival is eventually lost. Our statistical methodology enabled us to demonstrate both the initial, negative effect on longevity and the loss of this effect over time.
Although our results indicate that the 5-year survival of GCA patients is signifi cantly less than that of a control group, our results do not address whether GCA itself or consequences of treatment of GCA is directly responsible for this increase in mortality. Elderly individuals, such as those in our study population, often have comorbidities that affect longevity. Furthermore, although GCA typically runs a self-limited course of 1 -2 years, some patients experience spontaneous relapses during or after the 5 years following diagnosis ( 6 , 8 , 12 , 37 ) . One may hypothesize that because the disease is more likely to be active during the fi rst 5 years than during the subsequent 6 -10 years, mortality from GCA and its treatment is greatest during the fi rst 5 years following diagnosis. Based on our results, patients who survive the fi rst 5 years after diagnosis may have a mortality rate that refl ects that of other elderly patients in the general population ( 38 -40 ) .
We recommend that further studies be directed at identifying risk factors for early death after a diagnosis of GCA. Specifi c attention should be given to known vascular disorders, cardiac disease, and large vessel disease. Furthermore, genetic testing has proven to be useful in diagnosis or treatment of ophthalmic as well as vascular disorders, and development of such tests in the future may enhance our ability to identify risk factors for increased GCA-associated morbidity and mortality ( 41 -44 ) . Perhaps by identifying those patients at risk for early death, we can intervene before lifethreatening complications arise. 
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The authors gratefully acknowledge Jennifer Harmon, Geraldine P. Mineau, Richard Pimentel, and Tien Y. Wong for assistance with use of the UPDB and review of the manuscript. B.J.K. thanks Mark A. Supiano, MD, Chief, Division of Geriatrics, University of Utah, for his guidance and advice on this project. B.J.K. has listed everyone who contributed signifi cantly Figure 1 . Kaplan-Meier analysis to compare the cumulative survival curves of 44 biopsy-proven giant cell arteritis (GCA) patients (dashed line) to 4,400 controls (solid line). One-hundred controls were randomly selected for each of the 44 GCA patients after being matched by birth year and gender. The 5-year survival of GCA patients is signifi cantly reduced compared with that of the control group ( p < .001).
